Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…
-
-
Gavi signed agreement with Clover Biopharmaceuticals for supply to COVAX
On Jun. 30, 2021, Gavi, the Vaccine Alliance, announced that it had signed an advance purchase agreement with…
-
Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants
On Jun. 29, 2021, Moderna announced new results from in vitro neutralization studies of sera from individuals vaccinated…
-
India approves Moderna’s Covid-19 vaccine for emergency use
On Jun. 29, 2021, India announced it had authorized the emergency use of Moderna’s Covid-19 vaccine as it…
-
Altimmune announced update on AdCOVID phase 1 clinical trial
On Jun. 29, 2021, Altimmune provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19….
-
VBI Vaccines announced initial positive phase 1 data for its eVLP vaccine candidate against COVID-19
On Jun. 29, 2021, VBI Vaccines announced positive Phase 1 data from its Phase 1/2 trial of the…
-
Fostamatinib selected for NIH ACTIV-4 COVID-19 clinical trial
On Jun. 29, 2021, Rigel Pharma announced that fostamatinib, the Company’s novel oral spleen tyrosine kinase (SYK) inhibitor,…
-
Adjuvant developed with NIH funding enhanced efficacy of India’s COVID-19 vaccine
On Jun. 29, 2021, the National Institutes of Health announced that an adjuvant developed with its funding had…
-
First trial participants vaccinated with Oxford COVID-19 variant vaccine
On Jun. 28, 2021, the University of Oxford in partnership with AstraZeneca began vaccinations for a new phase…
-
Mixed Oxford/Pfizer vaccine schedules generated robust immune response against COVID-19
On Jun. 28, 2021, researchers running the University of Oxford-led Com-COV study reported that alternating doses of the…
-
Meridian resubmitted application to FDA for Emergency Use Authorization for Revogene SARS-CoV-2 molecular assay
On Jun. 28, 2021, Meridian Bioscience announced that it had re-submitted its application for Emergency Use Authorization (EUA)…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Genomics | Life Science History | Medicine | NIH | Therapeutics | U.S. Congress | Vaccine
COVID-19 PPE distribution
The COVID-19 PPE Distribution cartoon illustrates the confusion and complexity of distributing Personal Protective Equipment (PPE) to defend…
-
Oxford researchers identified levels of antibody protection required to prevent symptomatic COVID-19
On Jun. 25, 2021, researchers from the University of Oxford released their findings about the so-called ”correlates of…
-
Roche’s Actemra/RoActemra received FDA EUA for treatment of COVID-19 in hospitalised adults and children
On Jun. 25, 2021, Roche announced that the Food and Drug Administration (FDA) had issued an Emergency Use…
-
NIH began sudy of COVID-19 vaccination during pregnancy and postpartum
On Jun. 23, 2021, the National Institutes of Health (NIH) announced that an observational study had begun to…
-
NIH study suggested COVID-19 prevalence far exceeded early pandemic cases
On Jun. 22, 2021, National Institutes of Health researchers reported that the prevalence of COVID-19 in the U.S….
-
European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022
On Jun. 22, 2021, Moderna announced that the European Commission (EC) had purchased an additional 150 million doses…
-
BioReference Laboratories announces first COVID-19 testing program for cruise industry
On Jun. 22, 2021, BioReference Laboratories, an OPKO Health company, announced a COVID-19 testing program for U.S. based…
-
Gilead’s Veklury (Remdesivir) associated with reduction in mortality rate in hospitalized patients with COVID-19
On Jun. 21, 2021, Gilead Sciences announced positive data from three retrospective studies of the real-world treatment of…
-
Vibativ effectively helped treat secondary bacterial infections in COVID-19 patients
On Jun. 21, 2021, Cumberland Pharma released a series of case reports describing the effectiveness of Vibativ (telavancin)…
-
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
REGEN-COV phase 3 RECOVERY trial met primary outcome, improving survival in Hospitalized COVID-19 patients
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
-
Data published in NEJM showed Pfizer’s Tofacitinib met primary endpoint in Brazilian study in patients with COVID-19 pneumonia
On Jun. 16, 2021, Pfizer and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein announced…
-
RECOVERY trial found Regeneron’s monoclonal antibody combination reduced deaths for hospitalised COVID-19 patients
On Jun. 16, 2021, the University of Oxford announced the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial demonstrated…
-
U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…
-
Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates
On Jun. 15, 2021, Moderna and Magenta Investments, an industrial conglomerate in the United Arab Emirates (UAE), announced…
-
KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial
On Jun. 14, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that was recruiting volunteers in the…
-
University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration award
On Jun. 14, 2021, University of British Columbia researchers Dr. Jayachandran Kizhakkedathu, Dr. Caigan Du and Dr. Christopher…
-
Moderna submitted authorization application for its COVID-19 vaccine in adolescents in Switzerland
On Jun. 14, 2021, Moderna announced that it had submitted an authorization application to Swissmedic for use of…
-
Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…
-
Cocrystal’s COVID-19 antiviral CDI-45205 shown to be active against SARS-CoV-2 and prominent SARS-CoV-2 variants
On Jun. 14, 2021, Cocrystal Pharma announced that its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active…
